Fizer reporting a beat on revenue and earnings for its second quarter, but the pharmaceutical manufacturer is facing new hurdles with tariff threats and calls from President Trump to lower prices. Our own Julie Hyman and senior health reporter Anelie Kamlani spoke with the CEO about cost cutting efforts and the future of the firm. >> I would call it more productivity enhancement and margin expansion.Uh we do that by implementing three things. One it is focus. So we stop doing things that they are not that i ...